Make your money go further for just 25p per day

Up more 12,000% in a year, but is it really still good value?

02/11/2020 · Novacyt SA (NCYT) 

Coronavirus microscopic image

This Covid-19 testing specialist has been a major winner from the pandemic. With the shares up over 12,000% in the past 12 months, can they really still be considered good value, as some contend? Our research into the phenomena that is Novacyt reflects on the facts, opportunities and risks.


Novacyt SA (LON:NCTR, PAR:ALNOV) is an international diagnostics group involved in the sale of diagnostic and pathogen testing kits based on molecular and protein testing technologies. We have followed the stock with interest in our regular Coronavirus updates, since February 2020 when we commented on Novacyt’s big break.


While its main activities are principally based in the UK, the holding company is incorporated in France and ‘listed’ on AIM and Euronext Growth Paris stock markets. For…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Novacyt SA

A refocused business delivers

30/09/2022 · Company Insights

Having survived a near death experience several years ago, a manufacturer of specialist industrial equipment covered…


Better than expected

17/06/2022 · Company Insights

Some welcome good news at last for shareholders in this provider of online competitions to win…


More Company Insights

Bonkers Bargains: new team, new plan and firmer footing

09/07/2024 · Argentex Group PLC

Sign-up to our free email updates

SIGN UP